Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. has completed a study titled ‘Evaluation of Satisfaction With Rimegepant and Triptans Utilizing Migraine Buddy Retrospective Data.’ The study aimed to assess user satisfaction with the migraine treatments Nurtec (rimegepant) and triptans, using real-world data from the Migraine Buddy app. This research is significant as it provides insights into patient satisfaction in a real-life setting, which can guide treatment decisions.
The study tested the effectiveness of two acute migraine treatments: rimegepant, known commercially as Nurtec, and triptans. These medications are designed to provide short-term relief from migraine symptoms.
This observational study utilized a cohort model with a retrospective time perspective. It analyzed satisfaction data from users of the Migraine Buddy app, focusing on their experiences with the treatments. The primary purpose was to evaluate treatment satisfaction.
The study commenced on June 9, 2024, with primary completion on May 20, 2024, and results submitted by June 5, 2025. The last update was on August 20, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data analysis and reporting.
The completion of this study could influence Pfizer’s stock performance positively by showcasing the effectiveness of Nurtec in real-world settings, potentially boosting investor confidence. As the migraine treatment market is competitive, with several companies offering similar products, this study could give Pfizer a competitive edge.
The study is completed, with further details available on the ClinicalTrials portal.